Microbial Robotics is a global biotechnology firm with a presence in China, Europe, India, and the USA. We develop and attract synthetic biology-based technologies.
In mid-2016 we are opening and making freely available to the global scientific community our biopharmaceutical platform technologies via the Open Therapeutics™ crowd-sourcing web portal.
Open Therapeutics is an agnostic web portal service that reduces the cost and risk of developing and deploying therapeutics. By stimulating an economies of scale model and micro-pharma indigenous industries, the global population should experience lower prices and greater availability of life-saving drugs. While crowd-sourcing scientists around open biopharma technologies designed to enhance health, we collect and enhance important research, clinical, and interactive data.
Our MicrobialBots (BactoBots and ViruBots) can induce biomarker expression by cancer cells, kill cancer cells, clean water, produce chemicals, and build materials. MicrobialBots can be protected by a Genetics Rights Management (GeRM™) consumable powder system. Instead of shipping genetically modified organisms (GMO) across borders, GeRM enables local MicrobialBot manufacturing and distribution.
We also have an proteome platform to enable the discovery of essential proteins as potential antibiotic (Proteome Antibiotics) and anticancer candidate targets.
The Proteome Antibiotics platform is a joint effort of Microbial Robotics and Bacmine SL. Initially, this platform is focused on finding essential proteins required for pathogen survival. Researchers can target these essential proteins to develop therapeutic agents that will kill the pathogens. This includes even antibiotic resistant organisms. Our efforts include locating potential antibiotic targets for methicillin-resistant MRSA and multi-drug resistant tuberculosis (MDR-TB).
If you are an Innovator or Organization with intellectual property (IP) not being out-licensed, contact us today. Together, we can generate publications and proliferate science.